The English court said that in most cases, the drug manufacturer's strategy did not disrupt the drug patent linking system, but it also made some unfavorable findings.

Zhitongcaijing · 1d ago
The English court said that in most cases, the drug manufacturer's strategy did not disrupt the drug patent linking system, but it also made some unfavorable findings.